0
Deep & Emerging Tech·August 26, 2026·1 min read

MindRank’s oral GLP-1 is the furthest along any AI-native drug programme

Share

Taking an oral GLP‑1 from program start to Phase III in ~4.5 years on ~$23M is a concrete compression of both time and capital for AI-native drug discovery. Pharma and biotech teams should be recalibrating build-vs-partner decisions — especially for small-molecule programs where AI can shrink early-stage burn dramatically.